Review article: Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 18, Issue 2, 2003, Pages 10-14

  Allgayer, Hubert ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Rehaklinik Ob der Tauber   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DNA; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER PREVENTION; COLORECTAL CARCINOMA; CONFERENCE PAPER; DNA DAMAGE; DOSE RESPONSE; DRUG MECHANISM; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDEMIOLOGICAL DATA; HUMAN; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

EID: 0141539530     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.18.s2.1.x     Document Type: Conference Paper

References (30)

1. Boring CC, Squires TS, Tong T. Cancer Statistics 1994. Cancer J Clin 1994; 44: 7-26.
2. Potter JD on behalf of the panel. Food, Nutrition, and the Prevention of Cancer: a global perspective. World Cancer Research Fund and American Institute for Cancer Research, Washington DC, 1997.
3. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35: 950-4.
4. Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN. Mortality in ulcerative colitis. Gastroenterology 1982; 83: 36-43.
5. Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-8.
6. Munkholm P. Crohn's disease - occurrence, course and prognosis. An epidemiologic cohort study. Dan Med Bull 1997; 44: 287-302. (Thesis review.)
7. Langholz E. Ulcerative colitis. An epidemiological observational study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999; 46: 400-15. (Thesis review.)
8. Moody GA, Jayanthi V, Probert CS, MacKay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83.
9. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994; 107: 117-20.
10. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Therap 2000; 14: 145-53.
11. Allgayer H, Kruis W. Aminosalicylates: potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol 2002; 37: 125-31.
12. Ekbom A, Kornfield D. Sulphasalazine use as a preventive factor for colorectal cancer in ulcerative colitis patients - a review. Inflamm Bowel Dis 1996; 2: 276-8.
13. Muller A, Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest 2002; 20: 102-9.
14. Neumeister P, Albanese C, Balent B, Greally J, Pestell R. Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol 2002; 34: 1475.
15. Okayasu J, Ohkusa T, Kaijura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996; 39: 87-92.
16. Shinozaki M, Nagawa G, Watanabe T, Saki T, Muto T. Acetate-induced colitis promotes dimethylhydrazine-induced colonic tumors. Gastroenterology 1999; 116: A502. (Abstract.)
17. Vainio H, Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. Scand J Gastroenterol 1998; 33: 785-9.
18. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999; 13: 1397-402.
19. Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000; 32: 245-54.
20. Egan LJ, Mays DC, Huntoon MP, et al. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalazine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274: 26448-53.
21. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95: 3452-7.
22. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-9.
23. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases alpha and beta. Gastroenterology 2000; 119: 1209-18.
24. Lauritsen K, Hansen J, Ryde M, Rask Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984; 86: 1496-500.
25. Allgayer H, Höfer P, Schmidt M, Böhne P, Kruis W, Gugler R. Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 1992; 43: 259-62.
26. Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 735-40.
27. Allgayer H, Rang S, Klotz U, et al. Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci 1994; 39: 145-51.
28. Grisham MB. Effect of 5-aminosalicylic acid in ferrous-sulfate-mediated damage to deoxyribose. Biochem Pharmacol 1990; 39: 2060-3.
29. Allgayer H, Kolb M, Stuber V, Kruis W. Modulation of base hydroxylation by bile acids and salicylates in a model of human colonic mucosal DNA. Putative implications in colonic cancer. Dig Dis Sci 1999; 44: 761-7.
30. Nashibayashi H, Kamayama S, Shimomura G, et al. Decrease of oxidative DNA damage in human colonic mucosa with ulcerative colitis after the medical therapy. Gastroenterology 1999; 116: A475.